Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HIV

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
JP
  • HIV infection, in combination with other antiretrovirals (Tivicay Tablets 50 mg, applicant ViiV Healthcare K.K.)
Product first approved 2014pj.jiho.jp
EU
  • Tivicay with other antiretrovirals for HIV-infected adults, adolescents and children (now from 4 weeks and 3 kg)
Product first approved 2014EMA
CA
  • TIVICAY, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adults and in INSTI-naïve pediatric patients aged 4 weeks and older and weighing at least 3 kg.
Product first approved 2013Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (40)
HIV
NCT07393659 · ViiV Healthcare
2026-07-21 – 2032-09-14 · HIV Infections
What this study did
NCT07792096 · University College, London
2026-11 – 2029-12 · HIV Infection
What this study did
NCT06497465 · Johns Hopkins University
2025-09-18 – 2029-01-31 · Tuberculosis, HIV
What this study did
NCT04892654 · Chelsea and Westminster NHS Foundation Trust
2022-08-17 – 2027-11-30 · HIV-1-infection
What this study did
NCT06747507 · University of Nairobi
2025-09-01 – 2027-07 · HIV-1-infection
What this study did
NCT06250504 · Africa Health Research Institute
2024-02-27 – 2026-10 · HIV Infections
What this study did
NCT05735535 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2023-10-01 – 2025-09-15 · HIV Infections
What this study did
NCT04022967 · ANRS, Emerging Infectious Diseases
2020-11-17 – 2024-12-30 · HIV-1-infection
What this study did
NCT03016533 · ViiV Healthcare
2017-06-06 – 2024-12-24 · HIV Infections
What this study did
NCT04979468 · Societa' Italiana Di Malattie Infettive E Tropicali
2021-03-23 – 2024-04-01 · HIV-1-infection
What this study did
NCT04808973 · Fundação Bahiana de Infectologia
2021-07-01 – 2023-09-10 · HIV Infections, Pregnancy Related, Mother to Child Transmission
What this study did
NCT03249181 · University of Liverpool
2018-01-22 – 2023-09-05 · HIV-1-infection, Pregnancy Related
What this study did
NCT04034862 · University of Liege
2019-10-01 – 2023-06-30 · HIV Infections
What this study did
NCT01910402 · ViiV Healthcare
2013-08-22 – 2022-08-18 · Infection, Human Immunodeficiency Virus, HIV Infections
What this study did
NCT02831673 · ViiV Healthcare
2016-07-21 – 2022-08-15 · Infection, Human Immunodeficiency Virus, HIV Infections
What this study did
NCT03122262 · Professor Francois Venter
2017-01-16 – 2022-07-29 · HIV-1 Infection
What this study did
NCT02831764 · ViiV Healthcare
2016-07-18 – 2022-06-29 · Infection, Human Immunodeficiency Virus, HIV Infections
What this study did
NCT02227238 · ViiV Healthcare
2014-12-11 – 2022-02-14 · HIV Infections
What this study did
NCT03988452 · Makerere University
2019-07-30 – 2021-09-30 · Human Immunodeficiency Virus
What this study did
NCT02777229 · ANRS, Emerging Infectious Diseases
2016-07 – 2021-07 · HIV-1 Infection
What this study did
NCT03945981 · ViiV Healthcare
2019-07-02 – 2020-10-20 · HIV Infections
What this study did
NCT03048422 · National Institute of Allergy and Infectious Diseases (NIAID)
2018-01-19 – 2020-10-03 · HIV Infections
What this study did
NCT02178592 · ViiV Healthcare
2015-01-23 – 2020-03-06 · Infection, Human Immunodeficiency Virus, HIV Infections
What this study did
NCT02987530 · ANRS, Emerging Infectious Diseases
2017-04-11 – 2020-01-31 · HIV-1 Infection
What this study did
NCT02976259 · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
2017-01 – 2018-12 · HIV Infection Primary
What this study did
NCT02596334 · Centre Hospitalier Régional d'Orléans
2015-12-23 – 2018-06-23 · HIV
What this study did
NCT02486133 · Technical University of Munich
2015-07 – 2018-05-31 · HIV-Infection
What this study did
NCT02263326 · Babafemi Taiwo
2014-12 – 2017-09 · HIV Infection
What this study did
NCT01966822 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
2014-01 – 2015-10 · HIV-1 Infection
What this study did
NCT01499199 · ViiV Healthcare
2012-01 – 2014-05 · Infection, Human Immunodeficiency Virus
What this study did
NCT01568892 · ViiV Healthcare
2012-04-18 – 2013-12-16 · HIV Infections
What this study did
Other / comorbidity
NCT05193994 · Macquarie University, Australia
2022-02-24 – 2025-06-30 · Amyotrophic Lateral Sclerosis
What this study did
NCT06658977 · Macquarie University, Australia
2024-11-15 – 2025-06-03 · Amyotrophic Lateral Sclerosis, ALS
What this study did
Phase 2/3 (6)
HIV
NCT04337450 · PENTA Foundation
2022-04-22 – 2026-09-30 · HIV Infections
What this study did
NCT02259127 · PENTA Foundation
2016-09-20 – 2023-12-07 · HIV Infection
What this study did
NCT01837277 · Fundação Bahiana de Infectologia
2017-12-15 – 2021-09-30 · Severely Immunocompromised HIV Patients
What this study did
NCT02245022 · University of Liverpool
2017-03-14 – 2018-12-06 · HIV, Pregnancy
What this study did
NCT02069834 · Nantes University Hospital
2014-05 – 2017-10 · HIV Infection, HAART-treated, Virologically Controlled
What this study did
NCT02499978 · Stanford University
2016-05 – 2016-06 · HIV/AIDS
What this study did
Phase 2 (29)
HIV
NCT06805656 · Federal University of São Paulo
2026-07-15 – 2028-06-01 · Hiv, HIV I Infection
What this study did
NCT05993767 · PENTA Foundation
2024-12-11 – 2026-01-20 · HIV Infection
What this study did
NCT05630872 · National Institute of Allergy and Infectious Diseases (NIAID)
2024-02-13 – 2025-11-12 · HIV-associated Tuberculosis
What this study did
NCT04880785 · Fundacion SEIMC-GESIDA
2021-07-28 – 2024-04-09 · HIV Infections
What this study did
NCT04871113 · ViiV Healthcare
2021-06-22 – 2023-09-21 · HIV Infections
What this study did
NCT04900038 · ViiV Healthcare
2021-08-18 – 2023-05-11 · HIV Infections
What this study did
NCT05351684 · University of Liege
2019-01-01 – 2022-12-13 · HIV-1-infection
What this study did
NCT03991013 · University of Cape Town
2019-08-08 – 2022-10-27 · HIV Infections
What this study did
NCT05006170 · Chulalongkorn University
2021-08-03 – 2022-06-30 · Pediatric HIV Infection
What this study did
NCT03851588 · University of Cape Town
2019-12-19 – 2022-06-28 · HIV Infections, Tuberculosis
What this study did
NCT03602690 · ANRS, Emerging Infectious Diseases
2018-10-04 – 2022-04-11 · HIV/AIDS
What this study did
NCT04272242 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-02-27 – 2021-12-27 · HIV Infection, LTBI
What this study did
NCT03539224 · Instituto de Investigación Hospital Universitario La Paz
2017-11-02 – 2021-07-31 · HIV-1-infection
What this study did
NCT03549689 · Philip Grant
2019-08-01 – 2021-07-01 · HIV/AIDS, HIV-1-infection, Osteopenia
What this study did
NCT02583048 · National Institute of Allergy and Infectious Diseases (NIAID)
2016-08-15 – 2021-02-04 · Tuberculosis, HIV Infections
What this study did
NCT02551523 · University of Zurich
2016-11 – 2021-02 · Monotherapy, Dolutegravir, Primary HIV Infection, Treatment Efficacy
What this study did
NCT03224338 · Blueclinical, Ltd.
2017-04-05 – 2019-07-02 · HIV II Infection
What this study did
NCT02542852 · Castagna Antonella
2015-09 – 2017-12 · HIV-1 Infection
What this study did
NCT02582684 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2015-12-08 – 2017-09-26 · HIV-1 Infection
What this study did
NCT02572947 · Calmy Alexandra
2016-06 – 2017-09 · Human Immunodeficiency Virus, Dolutegravir, Monotherapy, Treatment Efficacy
What this study did
NCT02386098 · ViiV Healthcare
2015-07-08 – 2017-06-07 · HIV Infections
What this study did
NCT00951015 · ViiV Healthcare
2009-07-30 – 2016-12-22 · Infection, Human Immunodeficiency Virus
What this study did
NCT02566707 · Radboud University Medical Center
2015-08 – 2016-12 · HIV-1 Infection
What this study did
NCT00950859 · ViiV Healthcare
2009-08 – 2015-01 · Infection, Human Immunodeficiency Virus
What this study did
NCT00708110 · ViiV Healthcare
2008-06 – 2008-08 · Infection, Human Immunodeficiency Virus
What this study did
Other / comorbidity
NCT05652478 · National Institute of Allergy and Infectious Diseases (NIAID)
2026-09-24 – 2030-01-31 · Healthy Volunteer, Weight Gain, Metabolic Effects, Integrase Strand Transfer Inhibitors
What this study did
NCT07555431 · Carlos Brites
2026-05-07 – 2028-06 · HTLV-1 Infection, HTLV I Associated Myelopathies, HTLV I Associated T Cell Leukemia Lymphoma, Neuritis
What this study did
Phase 1/2 (9)
HIV
NCT02140255 · National Institute of Allergy and Infectious Diseases (NIAID)
2015-01-23 – 2031-12-31 · HIV Infection
What this study did
NCT07124559 · National Institute of Allergy and Infectious Diseases (NIAID)
2026-09-28 – 2028-11-15 · Tuberculosis
What this study did
NCT05674656 · ViiV Healthcare
2023-07-06 – 2028-05-03 · HIV Infections
What this study did
NCT05122026 · The Aurum Institute NPC
2024-01-17 – 2025-12-31 · HIV Seropositivity, Pregnancy, Tuberculosis Infection
What this study did
NCT05122767 · The Aurum Institute NPC
2023-05-24 – 2025-12-31 · Tuberculosis, HIV
What this study did
NCT05590325 · Desmond Tutu TB Centre
2022-09-12 – 2024-12-31 · Hiv
What this study did
NCT03760458 · National Institute of Allergy and Infectious Diseases (NIAID)
2020-09-09 – 2022-05-31 · HIV Infections
What this study did
Other / comorbidity
NCT04044001 · Michael Hoelscher
2019-11-15 – 2022-05-31 · Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis
What this study did
Phase 1 (61)
HIV
NCT06281834 · Brigham and Women's Hospital
2024-11-15 – 2027-06-01 · Pediatric HIV Infection, Latent Tuberculosis
What this study did
NCT05406583 · National Institute of Allergy and Infectious Diseases (NIAID)
2022-10-05 – 2025-05-22 · HIV
What this study did
NCT06450275 · Humanis Saglık Anonim Sirketi
2024-01-03 – 2024-03-07 · HIV Infections
What this study did
NCT04771754 · Chelsea and Westminster NHS Foundation Trust
2022-03-20 – 2024-01-10 · HIV-1-infection on Healthy Volunteers
What this study did
NCT04302896 · Rhonda Brand
2020-08-31 – 2021-09-30 · Medication Adherence, HIV
What this study did
NCT05030025 · Mylan Inc.
2021-08-01 – 2021-08-29 · HIV-1-infection
What this study did
NCT03921723 · ViiV Healthcare
2019-05-07 – 2019-07-25 · HIV Infections
What this study did
NCT03094507 · St Stephens Aids Trust
2017-04-19 – 2018-03-17 · HIV
What this study did
NCT03199690 · St. Stephens Clinical Research
2017-10 – 2018-03 · HIV-1-infection, Tuberculosis
What this study did
NCT03078556 · ViiV Healthcare
2017-03-27 – 2017-08-18 · Infection, Human Immunodeficiency Virus
What this study did
NCT03095638 · ViiV Healthcare
2017-05-03 – 2017-06-23 · HIV Infections
What this study did
NCT02893488 · ViiV Healthcare
2016-09-01 – 2016-11-25 · Infection, Human Immunodeficiency Virus
What this study did
NCT02242799 · University of Liverpool
2015-06 – 2016-09 · Malaria, HIV
What this study did
NCT02738931 · ViiV Healthcare
2016-05 – 2016-06 · Infection, Human Immunodeficiency Virus
What this study did
NCT02715479 · ViiV Healthcare
2016-04 – 2016-05 · Infection, Human Immunodeficiency Virus
What this study did
NCT02219217 · St Stephens Aids Trust
2014-10 – 2015-01 · HIV
What this study did
NCT02185300 · ViiV Healthcare
2014-07 – 2014-09 · Infection, Human Immunodeficiency Virus
What this study did
NCT02082808 · ViiV Healthcare
2014-03 – 2014-05 · Infection, Human Immunodeficiency Virus
What this study did
NCT02064374 · ViiV Healthcare
2014-02 – 2014-05 · Infection, Human Immunodeficiency Virus
What this study did
NCT01967771 · ViiV Healthcare
2013-10 – 2014-01 · Infection, Human Immunodeficiency Virus
What this study did
NCT01827540 · Tobira Therapeutics, Inc.
2013-03 – 2013-05 · HIV-infection/AIDS
What this study did
NCT01762995 · ViiV Healthcare
2012-12 – 2013-03 · Infection, Human Immunodeficiency Virus
What this study did
NCT01622790 · ViiV Healthcare
2012-06 – 2012-08 · Infection, Human Immunodeficiency Virus
What this study did
NCT01563328 · ViiV Healthcare
2012-03-01 – 2012-05-01 · Infection, Human Immunodeficiency Virus
What this study did
NCT01353716 · ViiV Healthcare
2011-06 – 2012-04 · Infection, Human Immunodeficiency Virus
What this study did
NCT01498861 · ViiV Healthcare
2011-12 – 2012-03 · Infection, Human Immunodeficiency Virus
What this study did
NCT01467518 · ViiV Healthcare
2011-12 – 2012-02 · Infections, Human Immunodeficiency Virus and Hepatitis
What this study did
NCT01467531 · ViiV Healthcare
2011-11 – 2012-02 · Infections, Human Immunodeficiency Virus and Hepatitis
What this study did
NCT01231542 · ViiV Healthcare
2011-05 – 2011-12 · Infection, Human Immunodeficiency Virus
What this study did
NCT01425099 · ViiV Healthcare
2011-09 – 2011-10 · Infection, Human Immunodeficiency Virus
What this study did
NCT01382238 · ViiV Healthcare
2011-06 – 2011-08 · Infections, Human Immunodeficiency Virus and Herpesviridae
What this study did
NCT01366547 · ViiV Healthcare
2011-06 – 2011-07 · Healthy Subjects, Infection, Human Immunodeficiency Virus
What this study did
NCT01231529 · ViiV Healthcare
2010-11-19 – 2011-06-04 · Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus, HIV Infections
What this study did
NCT01332565 · ViiV Healthcare
2011-04 – 2011-06 · Infection, Human Immunodeficiency Virus
What this study did
NCT01283100 · ViiV Healthcare
2011-03 – 2011-06 · Infection, Human Immunodeficiency Virus I
What this study did
NCT01214993 · ViiV Healthcare
2010-10 – 2010-11 · Infections, Human Immunodeficiency Virus and Tuberculosis
What this study did
NCT01209065 · ViiV Healthcare
2010-09 – 2010-11 · Infections, Human Immunodeficiency Virus and Herpesviridae
What this study did
NCT01098513 · ViiV Healthcare
2010-04 – 2010-07 · Infection, Human Immunodeficiency Virus
What this study did
NCT01098526 · ViiV Healthcare
2010-03-16 – 2010-05-26 · Infections, Human Immunodeficiency Virus and Herpesviridae
What this study did
NCT01068925 · ViiV Healthcare
2010-02-15 – 2010-04-05 · Infection, Human Immunodeficiency Virus, HIV Infections
What this study did
NCT00774735 · GlaxoSmithKline
2008-10 – 2008-12 · Healthy Subjects, Infection, Human Immunodeficiency Virus
What this study did
Other / comorbidity
NCT07532304 · Merck Sharp & Dohme LLC
2026-05-11 – 2026-07-23 · Healthy
What this study did
NCT02437110 · National Institute of Neurological Disorders and Stroke (NINDS)
2019-04-01 – 2023-05-09 · Amyotrophic Lateral Sclerosis
What this study did
NCT05236530 · Novartis Pharmaceuticals
2022-03-09 – 2022-10-17 · Malaria
What this study did
NCT07002229 · Henan Genuine Biotech Co., Ltd.
2021-12-09 – 2022-09-09 · Healthy
What this study did
NCT04147715 · Shionogi
2019-10-09 – 2020-09-29 · Healthy Volunteer
What this study did
NCT01459315 · University of North Carolina, Chapel Hill
2011-11 – 2012-12 · Healthy
What this study did
Phase 4 (46)
HIV
NCT07616739 · Fundación Huésped
2026-09-10 – 2028-10-15 · HIV-1-infection
What this study did
NCT02656511 · University of California, San Francisco
2015-12 – 2028-05 · HIV
What this study did
NCT06580873 · Saskatchewan Health Authority - Regina Area
2024-09-30 – 2027-10-31 · HIV-1-infection, Opioid Use Disorder
What this study did
NCT06485154 · University of Witwatersrand, South Africa
2024-06-01 – 2026-08-31 · HIV Prevention
What this study did
NCT05493969 · Shanghai Public Health Clinical Center
2022-08 – 2026-06 · Acquired Immunodeficiency Syndrome
What this study did
NCT06787976 · Instituto Mexicano del Seguro Social
2025-06-19 – 2026-01-25 · HIV, Insomnia, Anxiety
What this study did
NCT04746547 · University of KwaZulu
2021-08-19 – 2025-07-31 · Tuberculosis, Hiv
What this study did
NCT05898841 · Fundacion SEIMC-GESIDA
2023-05-26 – 2025-07-07 · HIV Infections, Fatty Liver Disease
What this study did
NCT04884139 · Fundacion SEIMC-GESIDA
2021-07-14 – 2025-03-13 · HIV-1-infection
What this study did
NCT04910711 · Botswana Harvard AIDS Institute Partnership
2021-10-21 – 2024-10-31 · Human Immunodeficiency Virus, Contraception, ART
What this study did
NCT04880395 · Fundación Huésped
2021-05-17 – 2024-05-07 · HIV-1-infection
What this study did
NCT04166474 · Helen Reynolds
2021-11-18 – 2024-02-07 · Hiv, Tuberculosis
What this study did
NCT03675815 · Kirby Institute
2019-12-05 – 2024-01-15 · HIV Infections
What this study did
NCT04826562 · Saint Michael's Medical Center
2021-09-26 – 2023-12-30 · Human Immunodeficiency Virus
What this study did
NCT04904406 · Thomas Benfield
2020-10-22 – 2023-12-01 · Hiv, HIV Infections, HIV Cardiomyopathy, Weight Change, Body, HIV Lipodystrophy, Cardiovascular Diseases
What this study did
NCT03017872 · Kirby Institute
2017-11-23 – 2023-10-31 · HIV Infections
What this study did
NCT04549467 · Fundacion IDEAA
2020-11-17 – 2023-09-30 · Hiv, HIV-1-infection
What this study did
NCT04585737 · Charlotte-Paige Rolle, MD
2020-10-05 – 2023-08-10 · HIV I Infection
What this study did
NCT04340388 · Augusta University
2020-09-17 – 2023-02-25 · HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
What this study did
NCT04903847 · Thomas Benfield
2021-02-02 – 2023-02-02 · Hiv, HIV Infections, HIV Lipodystrophy, Osteoporosis, Renal Insufficiency, Weight Gain, Obesity
What this study did
NCT04183738 · Kirby Institute
2021-02-01 – 2022-12-19 · HIV-infection/Aids, Human Herpesvirus 4 Infections, Cytomegalovirus Infections, Human Herpesvirus 8 Infection, Human Papilloma Virus
What this study did
NCT05295394 · Pedro Cahn
2019-05-22 – 2022-08-30 · HIV-1 Infection
What this study did
NCT03813979 · Radboud University Medical Center
2020-11-15 – 2021-12-31 · HIV-1-infection, Hepatic Impairment
What this study did
NCT04229290 · University of Nairobi
2020-02-12 – 2021-09-16 · HIV-1-infection
What this study did
NCT02659761 · University College Dublin
2016-11 – 2021-09 · Human Immunodeficiency Virus
What this study did
NCT03683524 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
2018-11-19 – 2021-08-10 · HIV-1 Infection
What this study did
NCT04225325 · ADRIANO LAZZARIN, MD
2018-05-07 – 2021-06-14 · HIV-1-infection
What this study did
NCT02519777 · National Institute of Allergy and Infectious Diseases (NIAID)
2016-04-21 – 2021-01-05 · HIV Infections
What this study did
NCT03360682 · Fundacion Clinic per a la Recerca Biomédica
2018-04-13 – 2020-05-21 · HIV-1-infection, Solid Organ Transplant
What this study did
NCT02337322 · Juan A. Arnaiz
2015-03-31 – 2019-12 · Acquired Immune Deficiency Syndrome Virus
What this study did
NCT02924389 · Emory University
2016-09 – 2019-09-11 · HIV
What this study did
NCT03033836 · Fundación Huésped
2015-12 – 2019-06-28 · HIV Infections
What this study did
NCT03218592 · University of North Carolina, Chapel Hill
2017-06-28 – 2018-12-07 · HIV/AIDS
What this study did
NCT03314064 · ViiV Healthcare
2016-12-08 – 2018-10-01 · Infection, Human Immunodeficiency Virus, HIV Infections
What this study did
NCT02098837 · St Stephens Aids Trust
2014-04 – 2017-12-04 · HIV
What this study did
NCT02500446 · University of Melbourne
2015-09-28 – 2017-09-30 · HIV
What this study did
NCT02509195 · St Stephens Aids Trust
2015-08-04 – 2017-07-24 · HIV
What this study did
NCT02370979 · University Hospital, Strasbourg, France
2015-02 – 2017-07 · HIV-1 Infection
What this study did
NCT02401828 · Erasmus Medical Center
2015-03 – 2017-07 · Human Immunodeficiency Virus
What this study did
NCT02351908 · St Stephens Aids Trust
2015-03 – 2017-04 · HIV
What this study did
NCT02211482 · Fundación Huésped
2014-10 – 2017-04 · HIV-1 Infection
What this study did
NCT02513147 · Hospital Universitari Vall d'Hebron Research Institute
2015-06 – 2016-11 · HIV-1
What this study did
NCT02211690 · Andrew Carr
2014-08 – 2016-02 · Human Immunodeficiency Virus
What this study did
NCT02285374 · St Stephens Aids Trust
2014-11 – 2015-12 · HIV
What this study did
NCT02487706 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
2015-06 – 2015-07 · HIV
What this study did
Early phase / not applicable (7)
HIV
NCT07618507 · Federal University of São Paulo
2022-04-13 – 2024-03-08 · HIV, HIV -1 Infection
What this study did
NCT02384395 · University of North Carolina, Chapel Hill
2015-09 – 2021-09-17 · HIV, Acute HIV Infection
What this study did
NCT03512964 · Johns Hopkins University
2016-11-29 – 2020-09-13 · Human Immunodeficiency Virus
What this study did
NCT02961829 · Federal University of São Paulo
2015-07 – 2020-03 · Chronic Infection, HIV
What this study did
NCT02404805 · University of Colorado, Denver
2016-02 – 2016-10 · HIV, Hepatitis C
What this study did
NCT01536873 · ViiV Healthcare
2012-06-14 – 2016-09-23 · Infection, Human Immunodeficiency Virus, HIV Infections
What this study did
Used as active comparator (12)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
HIV
NCT06203132 · ANRS, Emerging Infectious Diseases
2025-01-27 – 2029-01 · HIV-1-infection
What this study did
NCT04155554 · Azienda Ospedaliera Universitaria Senese
2020-01-29 – 2021-07 · HIV-1-infection
What this study did
Phase 2 (4)
HIV
NCT07202546 · ViiV Healthcare
2026-02-11 – 2032-07-09 · HIV Infections
What this study did
NCT06774872 · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
2025-04-30 – 2028-06-15 · HIV-1-infection
What this study did
NCT04493216 · ViiV Healthcare
2020-11-18 – 2023-05-29 · HIV Infections
What this study did
Phase 1 (1)
Other / comorbidity
NCT05168176 · The Affiliated Hospital of Qingdao University
2021-12-01 – 2022-01-31 · Healthy Volunteers
What this study did
Phase 4 (3)
HIV
NCT05630638 · University of Liverpool
2023-10-10 – 2028-07 · HIV
What this study did
NCT07673965 · University of Witwatersrand, South Africa
2026-10-05 – 2027-11-30 · HIV (Human Immunodeficiency Virus), Sleep
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
HIV
NCT01896921 · University of Maryland, Baltimore
2013-09 – 2018-12 · HIV
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for HIV: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component)): this drugApprovedSmall moleculeHIV integraseReliable signal
NCT01263015: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003).
NCT01449929: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 (Week 48): DTG 50 mg QD 90% vs DRV 800 mg + RTV 100 mg QD 83%
Amprenavir
ApprovedUS marketing discontinued
Small moleculeHIV proteasenot yet gradedNo reviewed efficacy summary in this indication
Bictegravir (Biktarvy)ApprovedSmall moleculeHIV integraseReliable signal
NCT03110380: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis).
NCT02607956: Week 48 HIV-1 RNA <50 copies/mL: 89.4% B/F/TAF vs 92.9% DTG + F/TAF; difference -3.5 percentage points (95.002% CI -7.9 to 1.0); prespecified non-inferiority margin 12%.
Bictegravir / Lenacapavir (Bixlenvo)ApprovedSmall moleculeHIV integrase, HIV capsidPartial signal
NCT05502341: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results).
Cabotegravir (Apretude)ApprovedSmall moleculeHIV integraseReliable signal
NCT02720094: Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.): Cabotegravir 13/2280 vs TDF/FTC 39/2281
Cabotegravir / Rilpivirine (Cabenuva)ApprovedSmall moleculeHIV integrase, HIV reverse transcriptaseWeak signal
NCT03299049: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results).
NCT02938520: Virologic failure (HIV-1 RNA >=50 copies/mL, FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 4 weeks vs abacavir/dolutegravir/lamivudine: 2.1% vs 2.5%, adjusted difference -0.4% (95% CI -2.8 to 2.1); non-inferior against the 6% margin (CT.gov posted results).
Darunavir (Prezista)ApprovedSmall moleculeHIV proteasePartial signal
NCT00110877: HIV RNA <400 copies/mL at Week 48 (per-protocol population): darunavir-ritonavir 77% (220/286) vs lopinavir-ritonavir 68% (199/293); estimated difference 9% (95% CI 2-16).
Doravirine (Pifeltro)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT02403674: Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033).
NCT02275780: Week 48 HIV-1 RNA <50 copies/mL: 83.8% doravirine vs 79.9% darunavir/ritonavir; treatment difference 3.913 percentage points (95% CI -1.590 to 9.415), non-inferiority margin -10 percentage points.
Doravirine / Islatravir (Idvynso)ApprovedSmall moleculeHIV reverse transcriptase, HIV-1 Reverse TranscriptasePartial signal
NCT05630755: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results).
NCT04233879: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 (Week 48): Group 1: DOR/ISL 88.9% vs Group 2: BIC/FTC/TAF 88.3%
Elvitegravir (Stribild)ApprovedSmall moleculeHIV integrasePartial signal
NCT01095796: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1%
Emtricitabine (Emtriva)ApprovedSmall moleculeHIV reverse transcriptasePartial signal
NCT00112047: Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants
Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada)ApprovedSmall moleculeHIV reverse transcriptasePartial signal
NCT00323544: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm.
Etravirine (Intelence)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT00254046: Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005
NCT00255099: Confirmed viral load <50 copies/mL at Week 24 (intention to treat): etravirine (TMC125) 62% (183/295) vs placebo 44% (129/296); difference 18% (95% CI 11-26; p=0.0003).
Fostemsavir (Rukobia)ApprovedSmall moleculeHIV gp120Partial signal
NCT02362503: Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort (Day 1 and Day 8): Randomized Cohort-fostemsavir 600 mg BID -0.791 Log10 copies per milliliter (c/mL) (95% CI -0.885 to -0.698) vs Randomized Cohort-Placebo -0.166 Log10 copies per milliliter (c/mL) (95% CI -0.326 to -0.007)
NCT01384734: HIV-1 RNA < 50 copies/mL at Week 24: fostemsavir 400 mg BID 80% (95% CI 66.3 to 90), 800 mg BID 69% (54.6 to 81.7), 600 mg QD 76% (62.5 to 87.2) and 1200 mg QD 72% (57.5 to 83.8) vs the atazanavir/ritonavir reference arm 75% (60.4 to 85.7).
Ibalizumab (Trogarzo)ApprovedMonoclonal antibodyCD4 receptorWeak signal
NCT02475629: Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF (Day 14): Open-Label Ibalizumab Plus OBR 82.5% (95% CI 67.72% to 92.66%)
Lenacapavir (Sunlenca)ApprovedSmall moleculeHIV capsidPartial signal
NCT04150068: Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Cohort 1A: Lenacapavir 87.5 percentage of participants | Cohort 1B: Placebo to Lenacapavir 16.7 percentage of participants
NCT04143594: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm (Week 54): Group 1: SC LEN+(F/TAF→ TAF) 90.4% vs Group 2: SC LEN + (F/TAF → BIC) 84.9% vs Group 3: Oral LEN + F/TAF 84.6% vs Group 4: B/F/TAF 92.0%; p=0.7178 (Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF), p=0.3900 (Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF), p=0.3797 (Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF) missed
Lenacapavir (Yeztugo)ApprovedSmall moleculeHIV capsidReliable signal
NCT04925752: HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025).
NCT04994509: HIV incidence: 0 infections in 2,134 on twice-yearly lenacapavir (0 per 100 PY; 95% CI 0.00-0.19) vs background incidence 2.41 per 100 PY (IRR 0.00; 95% CI 0.00-0.04; P<0.001) and vs F/TDF 1.69 per 100 PY (IRR 0.00; 95% CI 0.00-0.10; P<0.001) (PURPOSE 1, NEJM 2024).
Maraviroc (Selzentry / Celsentri)ApprovedSmall moleculeCCR5 co-receptorPartial signal
NCT00098293: Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population (Week 48): Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) — Less than 400 copies/mL: 61.5%; Less than 50 copies/mL: 55.8% | Maraviroc Twice Daily + CBV (DB) — Less than 400 copies/mL: 70.6%; Less than 50 copies/mL: 65.3% vs Efavirenz Once Daily + CBV (DB) — Less than 400 copies/mL: 73.1%; Less than 50 copies/mL: 69.3%
Raltegravir (Isentress)ApprovedSmall moleculeHIV integraseReliable signal
NCT00293254: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3)
NCT00293267: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.7% (95% CI 71.8 to 82.9) vs Placebo + OBT 41% (95% CI 32 to 50.5)
Rilpivirine (Edurant)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT00540449: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%.
NCT00543725: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48 (Week 48): TMC278 — Responder: 291/340; Virologic failure: 24/340; Death: 1/340; Discontinued due to AE: 8/340; Discontinued due to other reason than AE: 16/340 vs Efavirenz — Responder: 276/338; Virologic failure: 18/338; Death: 3/338; Discontinued due to AE: 21/338; Discontinued due to other reason than AE: 20/338
Somatropin (Serostim)ApprovedProtein / enzyme therapeuticGrowth hormone receptorPartial signal
NCT00082628: Change in visceral adipose tissue area at Week 12: -32.6 cm² Serostim (n=210) vs 0.5 cm² placebo (n=74), p<0.001. phase 3 result · pivotal pending
NCT01077960: Primary endpoint: mean change in trunk fat from baseline to week 12, -1.7 kg (SD 1.4; n=106; p<0.001). phase 3 result · pivotal pending
Tenofovir Alafenamide / Emtricitabine (Descovy)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT02842086: Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564)
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Partial signal
NCT00528957: Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48 (48 weeks): Tenofovir DF 83.3 percentage of participants | Stavudine or Zidovudine 91.8 percentage of participants | All TDF 85.4 percentage of participants missed
NCT00352053: Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA (Baseline to 24 Weeks): Tenofovir DF -1.58 log10 copies/mL (IQR -2.15 to -0.27) | Placebo -1.549 log10 copies/mL (IQR -2.36 to -0.34) missed
Tesamorelin (Egrifta WR)ApprovedPeptideGrowth hormone-releasing hormone (GHRH) receptorPartial signal
NCT00608023: Changes From Baseline in Fasting Blood Glucose at Week 52 (Baseline and Week 52): Tesamorelin 52 Weeks 0 mg/dL (Standard Deviation 16) missed
Tipranavir (Aptivus)ApprovedSmall moleculeHIV proteasePartial signal
NCT00144170: Treatment Response at Week 48 (after 48 weeks of treatment): Tipranavir(TPV)/Low Dose Ritonavir(r) 34.5% vs Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r) 15%
NCT00054717: Treatment Response at Week 48 (At week 48): Tipranavir(TPV)/Low Dose Ritonavir(r) 33.8% vs Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r) 16.2%
ACC017Phase 3Small moleculeHIV integrasePartial signal
NCT06719310: The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29.
Albuvirtide (Aikening)Phase 3PeptideHIV gp41Partial signal
NCT02369965: Primary, HIV-1 RNA <50 copies/mL at week 48 (mITT, interim analysis with 46 albuvirtide and 50 control patients at week 48): 80.4% (37/46) albuvirtide + lopinavir/ritonavir vs 66.0% (33/50) NRTIs + lopinavir/ritonavir; difference 14.4% (95% CI -3.0% to 31.9%) against a prespecified non-inferiority margin of -12%, met.
AlimatravirPhase 3Small moleculeHIV-1 Reverse TranscriptaseWeak signal
NCT06045507: Primary outcomes, safety (no formal efficacy test): participants with at least one adverse event 62/101 (3 mg), 69/101 (6 mg) and 66/99 (12 mg) monthly MK-8527 vs 31 on placebo; discontinuation due to an adverse event 0, 2 and 1 vs 2 (CT.gov posted results).
Azvudine (FNC)Phase 3Small moleculeHIV reverse transcriptasePartial signal
NCT04109183: 符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05)
Dapivirine (Dapivirine Vaginal Ring)Phase 3Small moleculeHIV reverse transcriptaseReliable signal
NCT01617096: HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007).
IslatravirPhase 3Small moleculeHIV-1 Reverse Transcriptasenot yet gradedNo reviewed efficacy summary in this indication
Islatravir / LenacapavirPhase 3Small moleculeHIV-1 Reverse Transcriptase, HIV capsidnot yet gradedNo reviewed efficacy summary in this indication
SemzuvolimabPhase 3Monoclonal antibodyCD4 receptorWeak signalNo reviewed efficacy summary in this indication
TeropavimabPhase 3Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
ZinlirvimabPhase 3Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
Elsulfavirine (Elpida)Phase 2/3Small moleculeHIV reverse transcriptasePartial signalNo reviewed efficacy summary in this indication
LeronlimabPhase 2/3Monoclonal antibodyCCR5 co-receptorWeak signal
NCT02483078: Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period (From baseline visit to week 1 visit): PRO 140 — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 64%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 36% | Placebo — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 23%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 77%
NCT02859961: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure (From T1 (first treatment administration) to week 48 (T48).): Part 1 - 350 mg Weekly Injections of PRO 140, Group A 23% | Part 1 - 525 mg Weekly Injections of PRO 140, Group B 43% | Part 1 - 700 mg Weekly Injections of PRO 140, Group C 45%
UlonivirinePhase 2/3Small moleculeHIV reverse transcriptaseWeak signalFeatured results are safety only in this race
10-1074Phase 2Monoclonal antibodyHIV envelopeWeak signalFeatured results are safety only in this race
3BNC117Phase 2Monoclonal antibodyHIV envelopePartial signal
NCT03041012: Co-primary 1, plasma HIV-1 RNA decay rate, ART+romidepsin+3BNC117 vs ART only: daily decay 16.9% (95% CI -27.3% to -4.93%) vs 10.0% (95% CI -14.9% to -4.86%) from day 10 to 24 (P=0.048); comparable from day 0 to 10 and day 24 to 90, met. Co-primary 2, change in intact HIV-1 provirus frequency from baseline to day 365: all groups decreased, with no significant differences between the groups, missed.
CL-197Phase 2Small moleculeHIV reverse transcriptaseWeak signalNo reviewed efficacy summary in this indication
DezecapavirPhase 2Small moleculeHIV capsidPartial signal
NCT06039579: Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969)
EnvafolimabPhase 2Monoclonal antibodyPD-L1Weak signalNo reviewed efficacy summary in this indication
HTI Vaccine (ChAdOx1.HTI / MVA.HTI)Phase 2VaccineHIV-1 conserved epitopes (HTI)Partial signal
NCT03204617: Primary, safety (grade 3 or 4 local and systemic reactions; no formal efficacy test): adverse events were mostly mild and transient, with no related serious adverse events. Secondary: HTI vaccines induced strong, broad CD4 and CD8 T-cell responses; all participants had detectable viral rebound during treatment interruption.
LipovirtidePhase 2PeptideHIV gp41Partial signalNo reviewed efficacy summary in this indication
LotivibartPhase 2Monoclonal antibodyHIV envelopeWeak signal
NCT04871113: Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69)
TMB-365 / TMB-380Phase 2CombinationCD4; HIV envelopenot yet gradedNo reviewed efficacy summary in this indication
TrosunilimabPhase 2Monoclonal antibodyα4β7 integrinPartial signalFeatured results are safety only in this race
VesatolimodPhase 2Small moleculeToll-like receptor 7 (TLR7) (agonist)Weak signalFeatured results are safety only in this race
VH4004280 (VH-280)Phase 2Small moleculeHIV capsidPartial signal
NCT06039579: Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11): Part 1a: VH4004280 Dose Level 1 — Baseline (Day 1): 5.004 log10 c/mL (Standard Deviation 0.4592); Maximum change compared to Baseline (Day 1): -1.056 log10 c/mL (Standard Deviation 0.4567) | Part 1a: VH4004280 Dose Level 2 — Baseline (Day 1): 4.923 log10 c/mL (Standard Deviation 0.5428); Maximum change compared to Baseline (Day 1): -1.391 log10 c/mL (Standard Deviation 0.6986) | Part 2a: VH4004280 Pre-specified Dose — Baseline (Day 1): 4.866 log10 c/mL (Standard Deviation 0.7696); Maximum change compared to Baseline (Day 1): -1.983 log10 c/mL (Standard Deviation 0.2171) vs Matching Placebo for VH4004280 — Baseline (Day 1): 4.636 log10 c/mL (Standard Deviation 0.6641); Maximum change compared to Baseline (Day 1): -0.07 log10 c/mL (Standard Deviation 0.0574)
VH4524184Phase 2Small moleculeHIV integrasePartial signal
NCT06214052: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): VH4524184 Dose 1 -1.17 Copies per milliliter (copies/mL) (Standard Deviation 0.46) | VH4524184 Dose 2 -2.15 Copies per milliliter (copies/mL) (Standard Deviation 0.254) | VH4524184 Dose 3 -2.31 Copies per milliliter (copies/mL) (Standard Deviation 0.463) vs Placebo -0.28 Copies per milliliter (copies/mL) (Standard Deviation 0.37)
JL18008Phase 1/2Protein / enzyme therapeuticIL-7 receptorWeak signalNo reviewed efficacy summary in this indication
LP-98Phase 1/2PeptideHIV gp41Partial signalNo reviewed efficacy summary in this indication
AGT103-TPhase 1Gene therapy / editingHIV proviral reservoir / autologous T cellsWeak signalFeatured results are safety only in this race
AinuovirinePhase 1Small moleculeHIV reverse transcriptaseWeak signalFeatured results are safety only in this race
AV000103A (ICVAX)Phase 1VaccineHIV antigensWeak signalFeatured results are safety only in this race
BNT168Phase 1VaccineHIV antigensnot yet gradedNo reviewed efficacy summary in this indication
BNT351Phase 1Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
CPT31Phase 1PeptideHIV gp41Weak signalFeatured results are safety only in this race
MGD014Phase 1Multispecific antibodyHIV envelope gp120 x CD3Weak signalFeatured results are safety only in this race
MGD020Phase 1Multispecific antibodyHIV envelope gp41 x CD3Weak signalFeatured results are safety only in this race
MK-4646Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication
UVAX-1107Phase 1VaccineHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
VH4770359Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Islatravir / Ulonivirine
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
YASO GEL
—(overall)
Small moleculeHIV gp120not yet gradedNo reviewed efficacy summary in this indication
Fosamprenavir (Lexiva / Telzir)DiscontinuedSmall moleculeHIV proteasePartial signal
NCT00450580: Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks (Week 48): FPV/RTV 1400/100 mg Once Daily (QD) + ABC/3TC FDC 600/300 mg Q — HIV-1 RNA <400 copies/mL: 81%; HIV-1 RNA >=400 copies/mL: 19% | FPV/RTV 700/100 mg BID + ABC/3TC FDC 600/300 mg QD — HIV-1 RNA <400 copies/mL: 82%; HIV-1 RNA >=400 copies/mL: 18%
NCT00363142: Percentage of Participants Not Meeting the Definition of Virologic Failure at or Prior to Week 24 (Week 24): FPV/r100 92.1% | FPV/r200 94.2%
VH4527079DiscontinuedMultispecific antibodyHIV entrynot yet gradedNo reviewed efficacy summary in this indication
ZegruvirimatDiscontinuedSmall moleculeHIV-1 Gag maturation (CA-SP1 cleavage)Partial signal
NCT06061081: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA). (From Day 1 to Day 8): VH3739937 Low Dose Group -116909.43 copies/milliliter (c/mL) (Standard Deviation 187489.611) | VH3739937 Medium Dose Group -130461.67 copies/milliliter (c/mL) (Standard Deviation 106486.489) | VH3739937 High Dose Group -126026.67 copies/milliliter (c/mL) (Standard Deviation 190725.475) vs Placebo Once Daily (QD) -428000 copies/milliliter (c/mL) | Placebo Single Dose (SD) -14200 copies/milliliter (c/mL)

Compare side by side

2 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Phase 3HIVRecruiting
Est. primary completion 2026-11-30 · NCT04892654 · CT.gov ↗
What to watch
December 2026 (2)
Phase 3HIVRecruiting
Est. primary completion 2026-12 · NCT06747507 · CT.gov ↗
What to watch
Phase 4HIVRecruiting
Est. primary completion 2026-12 · NCT06967753 · CT.gov ↗
What to watch
2027 (3)
February 2027 (1)
Phase 1HIVRecruiting
Est. primary completion 2027-02-01 · NCT06281834 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2HIVRecruiting
Est. primary completion 2027-03-01 · NCT06805656 · CT.gov ↗
What to watch
May 2027 (1)
Phase 4HIVActive not recruiting
Est. primary completion 2027-05 · NCT02656511 · CT.gov ↗
What to watch
2028 (6)
January 2028 (3)
Phase 1/2HIVRecruiting
Est. primary completion 2028-01-31 · NCT02140255 · CT.gov ↗
What to watch
Phase 2Healthy Volunteer, Weight Gain, Metabolic Effects, Integrase Strand Transfer InhibitorsRecruiting
Est. primary completion 2028-01-31 · NCT05652478 · CT.gov ↗
What to watch
Phase 3HIVRecruiting
Est. primary completion 2028-01-31 · NCT06497465 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2HTLV-1 Infection, HTLV I Associated Myelopathies, HTLV I Associated T Cell Leukemia Lymphoma, NeuritisRecruiting
Est. primary completion 2028-05 · NCT07555431 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1/2HIVRecruiting
Est. primary completion 2028-06-26 · NCT07124559 · CT.gov ↗
What to watch
October 2028 (1)
Phase 4HIVRecruiting
Est. primary completion 2028-10-15 · NCT07616739 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Phase 3HIVNot yet recruiting
Est. primary completion 2029-06 · NCT07792096 · CT.gov ↗
What to watch
2032 (1)
September 2032 (1)
Phase 3HIVRecruiting
Est. primary completion 2032-09-14 · NCT07393659 · CT.gov ↗
What to watch

See the full readout calendar ↗